AIM ImmunoTech (AIM)
(Real Time Quote from BATS)
$0.27 USD
+0.02 (6.85%)
Updated Sep 24, 2024 12:20 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for AIM ImmunoTech Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 1 | 1 | 1 |
Gross Profit | 0 | 0 | -1 | -1 | -1 |
Selling & Adminstrative & Depr. & Amort Expenses | 32 | 20 | 18 | 15 | 12 |
Income After Depreciation & Amortization | -32 | -20 | -19 | -15 | -12 |
Non-Operating Income | 3 | 0 | 0 | 1 | 3 |
Interest Expense | 0 | 0 | 0 | 1 | 0 |
Pretax Income | -29 | -19 | -19 | -14 | -10 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -29 | -19 | -19 | -14 | -10 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -29 | -19 | -19 | -14 | -10 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -32 | -20 | -18 | -14 | -11 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 1 | 1 | 1 |
Income After Depreciation & Amortization | -32 | -20 | -19 | -15 | -12 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 48.59 | 48.05 | 47.34 | 31.84 | NA |
Diluted EPS Before Non-Recurring Items | -0.60 | -0.40 | -0.40 | -0.45 | NA |
Diluted Net EPS (GAAP) | -0.60 | -0.40 | -0.40 | -0.45 | -2.62 |
Fiscal Year end for AIM ImmunoTech Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.05 | 0.04 | 0.07 | 0.05 | 0.04 |
Cost Of Goods | 0.01 | 0.01 | 0.01 | 0.03 | 0.00 |
Gross Profit | 0.04 | 0.03 | 0.05 | 0.02 | 0.04 |
SG&A, R&D, and Dept/Amort Expenses | 3.74 | 5.77 | 14.06 | 8.17 | 5.50 |
Income After SG&A, R&D, and Dept/Amort Expenses | -3.70 | -5.74 | -14.01 | -8.15 | -5.46 |
Non-Operating Income | 2.04 | -0.01 | 1.43 | 0.34 | 0.55 |
Interest Expense | 0.18 | 0.07 | 0.00 | 0.00 | 0.00 |
Pretax Income | -1.84 | -5.82 | -12.58 | -7.82 | -4.91 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -1.84 | -5.82 | -12.58 | -7.82 | -4.91 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -1.84 | -5.82 | -12.58 | -7.82 | -4.91 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 52.84 | 49.46 | 48.59 | 48.64 | 48.41 |
Diluted EPS Before Non-Recurring Items | -0.03 | -0.12 | -0.26 | -0.16 | -0.10 |
Diluted Net EPS (GAAP) | -0.03 | -0.12 | -0.26 | -0.16 | -0.10 |